Abstract #1837

Schmalfuss I, Maravilla K, Maldjian J, Anzalone N, Essig M, Kuhn M, Gustafsson L

Gadobenate dimeglumine (GBD) is a Gd contrast agent with higher relaxivity in blood compared with other approved Gd agents. To explore the clinical utility of increased R1, 151 patients with brain or spine disease underwent two MRI examinations, one with GBD and the other with gadopentetate dimeglumine (GPD). Three blinded neuroradiologists read all cases. Lesion-to-brain CNR was significantly greater after GBD than after GPD (p<0.0001), with 3 readers noting increases in enhancement over GPD of 22%, 25%, and 26%, respectively. Readers preferred GBD over GPD for lesion border delineation, definition of disease extent, visualization of lesion morphology, lesion enhancement, and global diagnostic preference (p<0.0001 for all). This study confirms the improved enhancement provided by gadobenate dimeglumine for CNS imaging.